GO
| HSI1 | 19,553.61 | +177.08 | 179.30B |
| HSCEI1 | 6,934.70 | +63.32 | 77.11B |
| Back Zoom + Zoom - Block Traded | |
|
2024-05-06 15:52:54 CICC noted in a report that WUXI APPTEC (02359.HK)'s 1Q net profit fell 10.4% YoY to RMB1.94 billion, in line with the broker's expectation. The WuXi Chemistry molecular pipeline continued to expand, while the new molecule business (TIDES) continued to increase its volume. The broker looked forward to the commercialisation of high-end therapeutic CTDMO projects, and maintained its 2024 and 2025 profit forecasts on the group. CICC kept its Outperform rating on WUXI APPTEC H-shares, but lowered its target price by 17.2% to HK$44.3 due to increased concerns over geopolitical risks. The new target price is equivalent to 11.5x 2024 and 10.2x 2025 projected P/E ratios respectively. ~ AAStocks Financial News Web Site: www.aastocks.com | |